Moderna

4.0

Score

2026-03-19

"Cited as an exemplary company that redefined itself as a technology company doing biology, successfully leveraging AI in vaccine production despite smaller scale."

Source: AI Transformation: Radical Change, Strategic Imperatives, and the 30% Rule

4.0

Score

2026-02-21

"Gained 24% due to good news from the FDA."

Source: Space Capitalism & US Tariff Reversal: Market Shifts & Future Outlook

3.0

Score

2026-02-16

"Stock rose significantly with confirmed growth outlook, better-than-expected COVID vaccine sales, positive cancer vaccine study data, and a strategic focus on international markets."

Source: AI, Commodities, and Market Shifts: Key Investment Insights

-3.0

Score

2026-02-12

"Experienced a setback with the FDA refusing to consider its flu vaccination for approval and a prior contract cancellation, impacting its strategy to fund earlier-stage mRNA developments."

Source: Shopify's AI Whiplash, Moderna's Regulatory Hurdles, and Investment Radar

-3.0

Score

2026-02-12

"FDA application refusal for a flu vaccine due to formal reasons, despite no safety/efficacy concerns."

Source: Market Dynamics: Cybersecurity, Pharma Hurdles, and Crypto Evolution

4.0

Score

2026-01-23

"Im Plus nach Vorstellung einer starken Phase-2-Studie für einen Hautkrebsimpfstoff, Aktie hat dieses Jahr bereits 80% zugelegt."

Source: Börsenupdate: VWs Cashflow, P&Gs Kampf, Tech-Sektor im Umbruch

3.0